This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday

Celcuity Inc.
MapLight Therapeutics, Inc.
First Tracks Biotherapeutics Inc
FEDERAL HOME LOAN MORTGAGE CORP
FEDERAL NATIONAL MORTGAGE ASSOC

Celcuity Inc.

CELC

0.00

MapLight Therapeutics, Inc.

MPLT

0.00

First Tracks Biotherapeutics Inc

TRAX

0.00

FEDERAL HOME LOAN MORTGAGE CORP

FMCC

0.00

FEDERAL NATIONAL MORTGAGE ASSOC

FNMA

0.00

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Mizuho analyst Dan Dolev initiated coverage on Federal National Mortgage Association (OTC:FNMA) with an Outperform rating and announced a price target of $10. Federal National Mortgage shares closed at $8.15 on Friday. See how other analysts view this stock.
  • Piper Sandler analyst Yasmeen Rahimi initiated coverage on First Tracks Biotherapeutics Inc (NASDAQ:TRAX) with an Overweight rating and announced a price target of $54. First Tracks shares closed at $22.38 on Friday. See how other analysts view this stock.
  • HC Wainwright & Co. analyst Raghuram Selvaraju initiated coverage on MapLight Therapeutics Inc (NASDAQ:MPLT) with a Buy rating and announced a price target of $45. MapLight Therapeutics shares closed at $30.70 on Friday. See how other analysts view this stock.
  • Mizuho analyst Dan Dolev initiated coverage on Federal Home Loan Mortgage Corp (OTC:FMCC) with an Outperform rating and announced a price target of $9. Federal Home Loan shares traded at $7.13 on Friday. See how other analysts view this stock.

Considering buying TRAX stock? Here’s what analysts think:

Photo via Shutterstock

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.